NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States.
+ 2 more risks
Adequate balance sheet with limited growth.
Share Price & News
How has NantKwest's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 26C's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 26C exceeded the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 26C exceeded the German Market which returned -20.6% over the past year.
Price Volatility Vs. Market
How volatile is NantKwest's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is NantKwest undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 26C's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 26C's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 26C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 26C is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 26C's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 26C is good value based on its PB Ratio (2.1x) compared to the DE Biotechs industry average (3.4x).
How is NantKwest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 26C is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 26C is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 26C is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 26C's revenue (79.4% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: 26C's revenue (79.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 26C's Return on Equity is forecast to be high in 3 years time
How has NantKwest performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 26C is currently unprofitable.
Growing Profit Margin: 26C is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 26C is unprofitable, but has reduced losses over the past 5 years at a rate of 11.6% per year.
Accelerating Growth: Unable to compare 26C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 26C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 26C has a negative Return on Equity (-54.52%), as it is currently unprofitable.
How is NantKwest's financial position?
Financial Position Analysis
Short Term Liabilities: 26C's short term assets ($55.8M) exceed its short term liabilities ($11.6M).
Long Term Liabilities: 26C's short term assets ($55.8M) exceed its long term liabilities ($10.9M).
Debt to Equity History and Analysis
Debt Level: 26C is debt free.
Reducing Debt: 26C had no debt 5 years ago.
Inventory Level: 26C has a high level of physical assets or inventory.
Debt Coverage by Assets: 26C's debt is covered by short term assets (assets are 3.1388400552911E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 26C has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 26C has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29.7% each year
What is NantKwest's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 26C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 26C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 26C's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 26C's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 26C's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Patrick Soon-Shiong (66yo)
Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSc, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the ...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD908.75K) is about average for companies of similar size in the German market ($USD757.78K).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
|Executive Chairman & CEO||5.08yrs||US$908.75k||61.55% $146.1m|
|Chief Financial Officer||1.83yrs||US$945.48k||0.031% $73.3k|
|VP, General Counsel & Corporate Secretary||2yrs||no data||no data|
|Senior Vice President Mergers and Acquisitions||4.58yrs||no data||no data|
|Senior Vice President of Medical Affairs - Pediatric||3.25yrs||no data||no data|
|Senior Vice President of Adult Medical Affairs||3.25yrs||no data||no data|
|Vice President of Research & Development||5.25yrs||US$956.80k||no data|
Experienced Management: 26C's management team is considered experienced (3.3 years average tenure).
|Executive Chairman & CEO||5.08yrs||US$908.75k||61.55% $146.1m|
|Lead Independent Director||no data||US$177.43k||0.012% $29.2k|
|Director||no data||US$169.70k||no data|
|Independent Director||4.75yrs||US$179.97k||0.10% $243.6k|
|Independent Director||6yrs||US$179.93k||0.26% $605.8k|
|Director||0.83yr||no data||no data|
Experienced Board: 26C's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.1%.
NantKwest, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NantKwest, Inc.
- Ticker: 26C
- Exchange: DB
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$256.056m
- Listing Market Cap: US$237.339m
- Shares outstanding: 98.48m
- Website: https://www.nantkwest.com
Number of Employees
- NantKwest, Inc.
- 3530 John Hopkins Court
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NK||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2015|
|26C||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2015|
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 08:10|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.